Literature DB >> 8164456

Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia.

R Bataille1, X G Zhang, J Wijdenes, J F Schved, B Klein.   

Abstract

Because IL-6 has been involved in the pathogenesis of acute monoblastic leukemia, we investigated the in vitro anti-proliferative effect and the in vivo anti-tumoral effect of an anti-IL-6 murine monoclonal antibody (mAb) in a patient with M5B type acute leukemia. In the current study, we clearly show the IL-6 dependence of monoblastic cell viability and proliferation in vitro in short-term cultures of malignant cells and the clinical activity of the anti-IL-6 murine mAb. The complete neutralization of IL-6 in vivo was associated with a transient but complete disappearance of malignant monoblastic cells in the peripheral blood, with improvement or even normalization of several other biological parameters of disease activity. No immunization against the anti-IL-6 murine mAb was observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8164456     DOI: 10.1007/bf02989668

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  7 in total

1.  Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies.

Authors:  J Wijdenes; C Clement; B Klein; B Morel-Fourrier; N Vita; P Ferrara; A Peters
Journal:  Mol Immunol       Date:  1991-11       Impact factor: 4.407

2.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors:  B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

3.  Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells.

Authors:  J H Jansen; J C Kluin-Nelemans; J Van Damme; G J Wientjens; R Willemze; W E Fibbe
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

4.  Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation.

Authors:  C E van der Schoot; P Jansen; M Poorter; M R Wester; A E von dem Borne; L A Aarden; R H van Oers
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

5.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

Authors:  B Klein; J Wijdenes; X G Zhang; M Jourdan; J M Boiron; J Brochier; J Liautard; M Merlin; C Clement; B Morel-Fournier
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

Review 6.  Biological and clinical aspects of interleukin 6.

Authors:  T Hirano; S Akira; T Taga; T Kishimoto
Journal:  Immunol Today       Date:  1990-12

7.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.